Shaare Zedek Medical Center
Jerusalem, 91031, Israel
NCT Number: NCT06500715
Chemotherapy-induced febrile neutropenia (CIFN) is a dangerous complication of many chemotherapy drugs, with current treatment with granulocyte colony-stimulating factors (G-CSFs) accompanied by adverse effects, primarily muscle and bone pain. Adult patients with sarcoma treated with doxorubicin-based chemotherapy have a high risk (>40%) for developing CIFN. Acupuncture has been shown to have a potentially myelo-protective effect on bone marrow during chemotherapy, though its effect on the incidence of CIFN-related hospitalization has yet to be examined. In the proposed study, patients with sarcoma will be randomly allocated (in a ratio of 1:1) to Group A, receiving acupuncture during cycles 1, 3, and 5; or Group B, during cycles 2, 4, and 6, with the study oncologist blinded regarding allocation. Acupuncture will be administered on the first day (d1) and the 8th day (d8) of the chemotherapy cycles, with press-tack needles on d1 to d8, and patients will be taught to self-treat with acupressure from d8 to the next cycle. The incidence and duration of hospitalization due to CIFN will be examined, as will adherence to the chemotherapy regimen; G-CSF-related pain; and other outcomes using 3 quality-of-life-focused questionnaires. The study findings will have important implications regarding the role of acupuncture in the treatment of patients treated with chemotherapy drugs with a high risk for CIFN, such as those used in the treatment of sarcoma.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Jerusalem, 91031, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Acupuncture will be administered bilaterally on points PC6, LI 4, CV6, SP6, SP10 and ST36 on the first day of each cycle (d1), prior to administration of chemotherapy; and on d8, each session lasting between 30 to 45 minutes. Patients will continue from d1 to d8 with press-tack acupuncture needles on points PC 6, LI4, SP 6 and ST 36. On d8, patients will again undergo acupuncture, and continue with self-acupressure on the same points as the press-tack needles, until the next chemotherapy cycle.
Other names: Acupuncture needle; Press-Tack needle; Self-Acupressure
Time frame: 3 weeks
Time frame: 3 weeks
Time frame: 3 weeks
Actual vs. planned dosage and interval between cycles
Time frame: 3 wseks
Patient-reported outcome measures
Time frame: 3 weeks
Patient-reported outcome measures
Time frame: 3 weeks
MYCaW narratives
Time frame: 3 weeks
Patient medical files
Contact information is provided by the study sponsor or research team.
Shaare Zedek Medical Center
Other
Acupuncture as add-on to GCS-F Treatment for Reducing Febrile Neutropenia-related Hospitalization in Patients Undergoing Doxorubicin-based Treatment for Sarcoma: a Randomized Crossover Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06697262
Agranulocytosis, Cytopenia
View Trial DetailsNCT06988826
Agranulocytosis, Antibiotic Therapy
View Trial DetailsNCT06450821
Agranulocytosis, Cytopenia
Leeds, West Yorkshire, United Kingdom
View Trial DetailsNCT06278896
Agranulocytosis, Antibiotic Stewardship
View Trial Details